Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
MB-CART 2219.1
/
Miltenyi Biotec
Welcome,
Profile
Billing
Logout
Diseases
Trials
Trials
News
||||||||||
CART2219.1
/
KK Women's and Children's Hospital
,
MB-CART 2219.1
/
Miltenyi Biotec
Manufacturing Characteristics and Early Outcomes of a Tandem aCD22-aCD19 CAR-T Therapy for Childhood and Adult Relapsed/Refractory Acute Precursor B Lymphoblastic Leukemia
(HCC Ballroom B; In-Person) - Dec 19, 2024 - Abstract #TCTASTCTCIBMTR2025TCT_ASTCT_CIBMTR_712;
An ongoing Phase II study will confirm the early efficacy and safety results. Multiomic analysis in a representative subset of patients suggests that cytotoxic effector potential of CAR-T is important for long-term response.